Gastrointestinal Cancer News

ORLANDO — Endoscopic therapy was equally effective in patients with Barrett’s esophagus who had intramucosal carcinoma or high-grade dysplasia, according to research presented at the World Congress of Gastroenterology at ACG 2017.

ORLANDO — Individuals in whom colonoscopy revealed both serrated colon polyps and high-risk adenomas showed a significantly higher risk for developing future high-risk adenomas, and may therefore have an increased risk for colorectal cancer than those with high-risk adenomas alone, according to research presented at the World Congress of Gastroenterology at ACG 2017.

A phase 3 trial designed to compare cabozantinib with placebo for patients with advanced hepatocellular carcinoma met its primary endpoint of OS.

ORLANDO — Despite the wide variety in guidelines for colorectal cancer, an expert at the Postgraduate Course prior to the World Congress of Gastroenterology at ACG 2017 said the best screening is ‘the one that gets done.’

ORLANDO — Knowing who to test, when to test and the implications of genetic testing give gastroenterologists the opportunity to proactively manage their patients with colorectal cancer, according to one expert at the GI Pathophysiology Course preceding the World Congress of Gastroenterology at ACG 2017.

NIH launched the Partnership for Accelerating Cancer Therapies, a 5-year public-private research collaboration.

A novel genetic testing strategy developed at University of Pittsburgh Medical Center, which sequences mutations in pancreatic cyst fluid before surgery, showed high accuracy for identifying cysts associated with a high risk for aggressive pancreatic cancer.

Patients with advanced cancer face a heavy burden of hospitalization in the year following diagnosis, study data showed.

Live phone calls were significantly more effective than text messages or letters for reminding people to complete their fecal immunochemical tests for at-home colorectal cancer screening in a randomized controlled trial.

Labetuzumab govitecan monotherapy appeared safe and demonstrated activity in heavily pretreated patients with metastatic colorectal cancer, according to phase 1/phase 2 study results published in Journal of Clinical Oncology.